In my previous post I had asked you to send an email to the HSE for a patient called Cathy Durkin, who needs acces to the cancer drug Ipilimumab.
The drug had been turned down by the National Centre for Pharmacoeconomics last year on the basis of cost, but a concerted campaign by oncologists and patients has led to a change of mind. The centre originally claimed that, at €85,000 per patient, it was too expensive given that a study in the New England Journal of Medicine found a median survival rate of 3.7 months extra for patients taking it.
You can read the article :.State reaches deal on cost with cancer drug producer
Thanks for those who sent an email to the HSE!.